← Leaderboards
Paul Brian
Cubist Pharmaceuticals, Inc.
$1,394,505
Attributed
$1,394,505
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,394,505 · 3
By mechanism
R44$900,000 · 1
R43$494,505 · 2
Top collaborators
No co-investigators on record.
Most similar at Cubist Pharmaceuticals, Inc.
Same institution · by research overlap
- Jianshi Tao$1,010,639
- David W Green$632,963
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionCyclic PeptidesCombinatorial ChemistryAntibioticsPlasmidsLaboratory MouseChemical Structure FunctionStreptomycesCytotoxicityBiotherapeutic AgentEndocarditisEnterococcusEscherichia ColiGram Negative BacteriaHost Organism InteractionBiotechnologyMicroorganism Mass CultureMicroorganism MetabolismMolecular CloningMutantNonblood LipoproteinOsteomyelitisPharmacokineticsArtificial Chromosomes
Grant awards (4)
Modification of Daptomycin by Combinatorial Biosynthesis$400,000
R44 · FY2005 · GM
Modification of Daptomycin by Combinatorial Biosynthesis$500,000
R44 · FY2004 · GM
Modification of daptomycin by combinatorial biosynthesis$258,205
R43 · FY2003 · GM
Structure activity relationships around lipopeptides$236,300
R43 · FY2003 · AI